Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street

Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Research and Clinical Interests
Targeting mutant BRAF and integrin signaling in melanoma.

Show Details

Publications

Most recent Peer-reviewed Publications

1. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells
2. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor
3. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
4. Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations.
5. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
6. The Yin-Yang of RAF inhibitors
7. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity
8. Meeting report from the 2011 international melanoma congress, Tampa, Florida
9. Axl of evil
10. Finding the root of the problem: the quest to identify melanoma stem cells.
11. Mechanisms of resistance to RAF inhibitors in melanoma
12. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells
13. Mind the BAP
14. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
15. Paying particle attention to novel melanoma treatment strategies
16. The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors
17. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway
18. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells
19. αB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells
20. FOXD3 is a mutant B-RAF-regulated inhibitor of G1-S progression in melanoma cells

View All Publications